Latest From Biotech Now

What’s Really Happening with the So-called ‘Blend Wall’? A Fuels America Briefing

Fuels-America-Briefing-July-11-Brent-1-300x200

The public dialog surrounding the Renewable Fuel Standard is robust- and filled with misinformation. On July 11, Rep. Lee Terry and Rep. Bruce Braley held the third of a series of briefings, which focused on what is really happening with the so-called ‘Blend Wall.’ The briefing consisted of five speakers, including BIO’s own Brent Erickson, Executive Vice President of the Industrial and Environmental Section. Opening remarks were given by Tom Buis, CEO of Growth Energy. Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,

BIO IP & Diagnostics Symposium

Final IPDX logo

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. The program will also explore some of the potential regulatory dimensions. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate. Where & Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Nationwide Track and Trace System is Urgently Needed

Jim Greenwood

Today’s pharmaceutical distribution supply chain is governed largely by a patchwork of state laws and regulations that allows criminals to enter markets with the lowest safety requirements to inject counterfeit, unsafe, and potentially lethal products into the national supply chain. The state-by-state system is both onerous and ineffective, and the risk it poses to public health from counterfeiters can no longer be ignored. In a recent opinion piece for Roll Call, I write that: “Congress Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

BIO Joins Alliance for Fair Trade with India

shutterstock_26191726

BIO recently joined the Alliance for Fair Trade with India along with the U.S. Chamber of Commerce, the National Association of Manufacturers, Solar Energy Industries Association, and others. The new Alliance website states: Over the last year, policymakers and courts in India have engaged in a persistent pattern of discrimination that is hurting a wide range of manufacturing and services industries and jobs in the United States. India has recently mandated domestic content rules that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,